Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivermectin in SARS-CoV-2 Infection (IFORS)
NCT04431466Phase 2Terminated
- Sponsor
- Universidade Federal de São Carlos
- Start
- Jul 2020
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ivermectin in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Universidade Federal de São Carlos. Primary endpoint: Undetectable viral load during 7 days of follow-up. Started Jul 2020; status: terminated.
02
Drugs
ivermectin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04431466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04431466.